Showing 5281-5290 of 5798 results for "".
- AMA Calls for Design Overhaul of Electronic Health Records to Improve Usabilityhttps://practicaldermatology.com/news/20140917-ama_calls_for_design_overhaul_of_electronic_health_records_to_improve_usability/2459115/The AMA has called for solutions to EHR systems that have neglected usability as a necessary feature. Physicians need better designed EHR systems, the AMA has responded by releasing a new framework outlining eight priorities for improving EHR usability to benefit caregivers and patients.<
- The ISDS Welcomes the Dermatology Community to Jerusalemhttps://practicaldermatology.com/news/20140917-the_international_society_for_dermatologic_surgery_welcomes_the_dermatology_community_to_jerusalem/2459116/The 35th Annual International Society for Dermatologic Surgery (ISDS) Congress will be held in Jerusalem from October 22-24, 2014. The ISDS will have the newest and latest techniques dermatologic surgery, skin cancer surgery, laser surgery, hair transplantation, varicose veins, lipolysis,
- MELA Sciences to Provide Corporate Overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conferencehttps://practicaldermatology.com/news/20140917-mela_sciences_to_provide_corporate_overview_at_the_craig-hallum_capital_groups_2014_alpha_select_conference/2459118/Rose Crane, CEO of MELA Sciences, will provide a corporate overview at the Craig-Hallum Capital Group's 2014 Alpha Select Conference in New York City. Crane will discuss the latest FDA Pre-Market Approval of the MelaFind® System. To learn more go to:
- Late Stage Skin Cancers on the Rise in the UK: World Congress on Cancers of the Skinhttps://practicaldermatology.com/news/20140917-late_stage_skin_cancers_on_the_rise_in_the_uk_world_congress_on_cancers_of_the_skin/2459119/Advanced-stage skin cancers are on the rise in the UK, according to two studies presented this month at the World Congress on Cancers of the Skin in Edinburgh, Scotland. The findings highlight an urgent need to publicise self-check and early detection messages, the The Skin Cancer Foundation says.
- Novan's Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model: Presentationhttps://practicaldermatology.com/news/20140909-novans_nitric_oxide_drug_candidate_inhibits_growth_of_papillomavirus_in_translational_animal_model_presentation/2459124/Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced that Novan's nitric oxide drug candidate SB206 was shown to inhibit papilloma growth in a preclinical animal study. About two-thirds of healthy American adults are infected with human papillom
- Novan to Present Antiviral Preclinical Results of Nitric Oxide-Releasing Drug Candidates for the Treatment of Papillomavirushttps://practicaldermatology.com/news/20140903-novan_to_present_antiviral_preclinical_results_of_nitric_oxide-releasing_drug_candidates_for_the_treatment_of_papillomavirus/2459131/Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, will present antiviral data from a preclinical animal study at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), ta
- Solace International Issues Recall of Dermatend Original and Dermatend Ultrahttps://practicaldermatology.com/news/20140902-solace_international_issues_recall_of_dermatend_original_and_dermatend_ultra/2459134/Solace International, Inc. is voluntarily recalling all lots of Dermatend Original and Dermatend Ultra in all sizes and dosage form to the distributor/wholesaler level. A mole should be removed under the supervision of a dermatologist. Dermatend is not FDA approved, thus has not
- MELA Sciences and Columbia University Imaging Experts Columbia Team Explore Potential Next Generation MelaFind Enhancementshttps://practicaldermatology.com/news/20140902-mela_sciences_and_columbia_university_imaging_experts_columbia_team_explore_potential_next_generation_melafind_enhancements/2459135/MELA Sciences, Inc.has executed a research agreement with Columbia University in which MELA and Columbia will collaborate to explore potential next generation capabilities and features of the MelaFind system and other enhancements to the system's range and ease of use. The company will have exclu
- Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase III Psoriasis Studieshttps://practicaldermatology.com/news/20140822-lillys_ixekizumab_superior_to_etanercept_and_placebo_in_phase_iii_psoriasis_studies/2459137/Eli Lilly and Company's ixekizumab was found to be statistically superior to etanercept and placebo on all skin clearance measures in pivotal, Phase III UNCOVER studies in moderate-to-severe plaque psoriasis. "These data are important for people suffer
- The American Med Spa Association Launches a New Comprehensive Websitehttps://practicaldermatology.com/news/20140821-the_american_med_spa_association_launches_a_new_comprehensive_website/2459138/The American Med Spa Association launched a new user-friendly website it says will address all industry needs. The new user-friendly website features a more accessible format for members to obtain up to date information on their state's rules and regulations within the medical spa indust